First Alzheimer's blood test available in US in June
The first blood test to help diagnose Alzheimer's disease will be available from late June in the US. PHOTO: ISTOCKPHOTO
WASHINGTON – The first blood test to help diagnose Alzheimer's disease will be available from late June in the US following regulatory clearance for its use last week, according to the Japanese company behind the innovation.
The test will initially be available at about 50 American research institutes and hospitals that specialise in Alzheimer's disease, Mr Goki Ishikawa, head of Fujirebio Holdings Inc., a unit of Japan's H.U. Group Holdings Inc., said in an interview on May 20. It's partnering with bigger rivals like Beckman Coulter Inc. to help develop and manufacture their products, he said.
The Food and Drug Administration cleared the blood test to help diagnose Alzheimer's disease last week, potentially making it easier to find and treat patients with the memory-robbing disease that affects nearly seven million Americans.
The test was cleared for use in people at least 55 years old and who exhibit signs of the disease. It is designed to detect amyloid, a protein that can build up in the brain and is a hallmark of Alzheimer's, the most common form of dementia in the elderly.
The process, which takes roughly 30 minutes from drawing the blood to diagnosis, will be available to patients at a fraction of the cost of a PET scan. The method is viewed as a critical step in making new types of Alzheimer's treatments widely accessible.
Until now, patients typically have to get a specialised PET scan to detect amyloid in their brains or undergo cerebrospinal fluid tests, both of which are more expensive and invasive. The lack of quick and easy tests has until now slowed the rollout of new Alzheimer's drugs like Eisai Co. and Biogen Inc.'s Leqembi and Eli Lilly & Co.'s Kisunla.
The company plans to file data to seek approvals in Japan as early as August and Europe within this year, Mr Ishikawa said. In China, Fujirebio's undisclosed partner will probably submit data to regulators next year, he added. In India, it partners with Agappe Diagnostics Ltd.
'We have a presence in Japan but that's not necessarily the case in markets overseas,' said Mr Ishikawa. 'We can't get the market shares by ourselves, but if we supply the raw materials to partners, we can benefit through them.' BLOOMBERG
Join ST's Telegram channel and get the latest breaking news delivered to you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
6 hours ago
- Business Times
Harvard crackdown: Can Singapore become its own intellectual leader?
THE US has long been a global science leader, with this best exemplified by its scientists creating a Covid-19 vaccine – amid a pandemic no less – within a year. Given that vaccine developments typically take a decade or more, this is nothing short of a feat, and something that has been decades in the making – a result of generous state funding for research and an openness to talent, among other factors. This is why US President Donald Trump's crusade against Harvard University and other top American institutions should give us pause, even if the fate of Ivy League colleges an ocean away may not seem, at first, to have major repercussions for Singapore. Alongside the on-and-off-again tariffs, immigration crackdown and slashing of government budgets, some observers may regard Trump's first 140 days as part of a natural ebb and flow in American politics. After all, the country has seen its fair share of upheavals in the last 249 years, having survived a civil war in the mid-19th century and, over 100 years later, lived through a particularly turbulent 1968 punctuated by two assassinations, heightened social unrest over the Vietnam War and issues related to values and race. Yet, even Americans appear spooked themselves. Experts and ordinary people, regardless of political leanings, are voicing concern that American democracy is being eroded and possibly sliding into autocracy, multiple surveys have shown. In particular, the administration's clampdown on its universities could have far-reaching consequences. America's embrace of diversity had long been part of its DNA, a trait that has drawn the world's brightest minds who, in turn, have kept its universities at the forefront of research and innovation that have resulted in life-saving drugs and key inventions. Some of these foreign talents remain in the country in pursuit of the American dream; others, equipped with new knowledge and skills, return home for the betterment of their motherland. Singapore too, has benefited from the return of US-trained scholars who have gone on to helm senior positions in government and the private sector. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up But all that is now in peril under the Trump administration, which has threatened to cut funding and foreign student quotas – actions that portend a brain drain and a possible curtailment of its research capabilities. The question is how long this crusade would last, and whether the damage wrought would be permanent. Meanwhile, foreign students and postgraduates have been targets of an immigration crackdown. Some have had their visas revoked, and others fear they would not be able to re-enter if they leave. Prospective students are naturally reconsidering their choice, given the uncertainty and apparent lack of transparency. Even researchers are hesitating to visit; a French scientist was denied entry in March because he had criticised the administration in a text message. In 2022 and 2023, Singapore sent about a quarter of its Public Service Commission scholarship recipients to the US, and many more students went at their own expense. But the latest developments raise the question whether the city-state should reconsider its reliance on the US for intellectual leadership. The imbroglio should also prompt Singapore to look afield at Europe and China, which are now seizing the opportunity to woo students and researchers seeking alternatives. A small but growing number of Singapore students have headed for European and Chinese universities over the years. And not least, Singapore might also take a leaf out of their playbook and do the same, since having a strong talent mix is what would augment its universities' standing. Rather than looking mainly to the West for intellectual leadership, Singapore has now an opportunity to build up its own for the region.
Straits Times
a day ago
- Straits Times
US NIH director hopes administration will settle with universities over suspended grants
U.S. National Institutes of Health (NIH) Director Jay Bhattacharya testifies before a Senate Appropriations Committee hearing on U.S. President Donald Trump's budget request for the NIH, on Capitol Hill in Washington, D.C., U.S., June 10, 2025. REUTERS/Kent Nishimura WASHINGTON - National Institutes of Health Director Jay Bhattacharya told a U.S. Senate panel on Tuesday he was hopeful that President Donald Trump's administration would reach a settlement with universities that have had research grants suspended. "I'm very hopeful that a resolution being made with the universities where those decisions have been made, where those grants have been paused," Bhattacharya said while appearing at a hearing of the Senate Appropriation Committee's Subcommittee on Labor, Health and Human Services, Education, and Related Agencies on the NIH's 2026 budget request. Dozens of scientists, researchers and other employees at the NIH issued a rare public rebuke on Monday ahead of the hearing, criticizing the Trump administration for major spending cuts that "harm the health of Americans and people across the globe," politicize research and "waste public resources." The NIH has terminated 2,100 research grants totaling about $9.5 billion and an additional $2.6 billion in contracts since Trump took office Jan. 20, they said in the letter. The contracts often support research, from covering equipment to nursing staff working on clinical trials. The White House wants to reduce U.S. health spending by more than a quarter next year, with the NIH facing the brunt with a cut of $18 billion, or 40%, from this year's budget, leaving it with $27 billion. The Trump administration wants to cut funding altogether for four of the agency's 27 institutes and centers while consolidating others into five new ones. REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.
Straits Times
2 days ago
- Straits Times
Kennedy's firing of independent CDC advisers undermines vaccine confidence, experts say
FILE PHOTO: U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. attends a Senate Health, Education, Labor & Pensions Committee hearing on the Department of Health and Human Services budget, on Capitol Hill in Washington, D.C., U.S., May 14, 2025. REUTERS/Leah Millis CHICAGO - U.S. Health Secretary Robert F. Kennedy Jr.'s dismissal of an independent panel of experts citing the goal of restoring trust in vaccines could undermine confidence in those available now, putting Americans at risk of preventable infectious diseases, public health experts and others said on Monday. Kennedy, a longtime vaccine skeptic, said in a commentary published in the Wall Street Journal that he was firing all 17 members of the Advisory Committee for Immunization Practices (ACIP) at the Centers for Disease Control and Prevention "to re-establish public confidence in vaccine science.' The committee reviews vaccines approved by the U.S. Food and Drug Administration and makes recommendations to the CDC on their use. "I fear that there will be human lives lost here because of this," said Dr. Sean O'Leary, chair of the American Academy of Pediatrics' Committee on Infectious Diseases. "It is a special kind of irony that he is saying he is doing this to restore trust, given that he is, as an individual, more responsible for sowing distrust in vaccines than almost anyone I can name," O'Leary said. O'Leary said pediatricians have already been fielding calls from parents who are confused about conflicting announcements earlier this month narrowing the use of COVID-19 vaccines for healthy children and pregnant women. "This is only going to add to that," he said. A U.S. Department of Health and Human Services spokesman said the agency is prioritizing public health, evidence-based medicine, and restoring public confidence in vaccine science. The firing of the entire vaccine advisory committee comes just weeks before a scheduled public meeting in which advisers were expected to weigh in and vote on a number of decisions, including the 2025-26 COVID-19 vaccine boosters. The health agency said the committee will meet as scheduled on June 25-27, but it is unclear who would serve on that panel or how they have been vetted for conflicts of interest. The agency said it would replace them with new members currently under consideration. Fired ACIP member Noel Brewer, a professor of public health at the University of North Carolina, said it took about 18 months from the time he applied until he was serving as an ACIP member. Senate Minority Leader Chuck Schumer decried the changes. "Wiping out an entire panel of vaccine experts doesn't build trust — it shatters it, and worse, it sends a chilling message: that ideology matters more than evidence, and politics more than public health," he said in a statement. Former CDC Director Dr. Thomas Frieden called out Kennedy's "false claims" in the Wall Street Journal piece, saying the panel was rife with conflicts of interest. Most of the panel was appointed last year, the CDC website shows. "Make no mistake: Politicizing the ACIP as Secretary Kennedy is doing will undermine public trust under the guise of improving it." REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.
